Treatment of Discoid Lupus Erythematosus with Localized Skin Lesions — Not Pregnant, Not Breastfeeding
Clinical scenario
This protocol addresses patients presenting with localized skin lesions of discoid lupus erythematosus. There is no severe or widespread skin involvement, no significant risk of scarring, and no indication of progression to systemic disease. The patient is neither pregnant nor breastfeeding.
Treatment approach
Management in this setting involves thalidomide, preferably used alongside another systemic therapy. The complete regimen — including sequencing, dose adjustments, and monitoring requirements — is available in the full structured protocol.
References
- Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes.
- We recommend thalidomide for selected refractory CLE patients, preferably in addition to antimalarials.
- We suggest a starting dose of 100 mg per day and, after clinical effectiveness, to taper to a minimum dose.